PMID- 27626701
OWN - NLM
STAT- MEDLINE
DCOM- 20180213
LR  - 20201209
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 7
IP  - 43
DP  - 2016 Oct 25
TI  - CDCP1 is a novel marker of the most aggressive human triple-negative breast 
      cancers.
PG  - 69649-69665
LID - 10.18632/oncotarget.11935 [doi]
AB  - CDCP1, a transmembrane noncatalytic receptor, the expression of which has been 
      associated with a poor prognosis in certain epithelial cancers, was found to be 
      expressed in highly aggressive triple-negative breast cancer (TNBC) cell models, 
      in which it promoted aggressive activities-ie, migration, invasion, 
      anchorage-independent tumor growth, and the formation of vascular-like structures 
      in vitro. By immunohistochemical (IHC) analysis of 100 human TNBC specimens, 
      CDCP1 was overexpressed in 57% of samples, 38% of which exhibited a gain in CDCP1 
      copy number by fluorescence in situ hybridization (FISH). CDCP1 positivity was 
      significantly associated between FISH and IHC. CDCP1 expression and gains in 
      CDCP1 copy number synergized with nodal (N) status in determining disease-free 
      and distant disease-free survival. The hazard ratios (HRs) of the synergies 
      between CDCP1 positivity by IHC and FISH and lymph node positivity in predicting 
      relapse did not differ significantly, indicating that CDCP1 overexpression in 
      human primary TNBCs, regardless of being driven by gains in CDCP1, is for a 
      critical factor in the progression of N-positive TNBCs. Thus, CDCP1 is a novel 
      marker of the most aggressive N-positive TNBCs and a potential therapeutic 
      target.
FAU - Turdo, Federica
AU  - Turdo F
AD  - Molecular Targeting Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, 
      Italy.
FAU - Bianchi, Francesca
AU  - Bianchi F
AD  - Molecular Targeting Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, 
      Italy.
AD  - Dipartimento di Scienze Biomediche per la Salute, Universita degli Studi di 
      Milano, Milan, Italy.
FAU - Gasparini, Patrizia
AU  - Gasparini P
AD  - Tumor Genomics Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, 
      Italy.
FAU - Sandri, Marco
AU  - Sandri M
AD  - Molecular Targeting Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, 
      Italy.
FAU - Sasso, Marianna
AU  - Sasso M
AD  - Molecular Targeting Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, 
      Italy.
FAU - De Cecco, Loris
AU  - De Cecco L
AD  - Functional Genomic Core Facility, Fondazione IRCCS Istituto Nazionale dei Tumori, 
      Milano, Italy.
FAU - Forte, Luca
AU  - Forte L
AD  - Molecular Targeting Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, 
      Italy.
FAU - Casalini, Patrizia
AU  - Casalini P
AD  - Molecular Targeting Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, 
      Italy.
FAU - Aiello, Piera
AU  - Aiello P
AD  - Molecular Targeting Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, 
      Italy.
FAU - Sfondrini, Lucia
AU  - Sfondrini L
AD  - Dipartimento di Scienze Biomediche per la Salute, Universita degli Studi di 
      Milano, Milan, Italy.
FAU - Agresti, Roberto
AU  - Agresti R
AD  - Division of Surgical Oncology, Breast Unit, Fondazione IRCCS Istituto Nazionale 
      dei Tumori, Milano, Italy.
FAU - Carcangiu, Maria Luisa
AU  - Carcangiu ML
AD  - Division of Breast Anatomy Pathology, Fondazione IRCCS Istituto Nazionale dei 
      Tumori, Milano, Italy.
FAU - Plantamura, Ilaria
AU  - Plantamura I
AD  - Start-Up Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
FAU - Sozzi, Gabriella
AU  - Sozzi G
AD  - Tumor Genomics Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, 
      Italy.
FAU - Tagliabue, Elda
AU  - Tagliabue E
AD  - Molecular Targeting Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, 
      Italy.
FAU - Campiglio, Manuela
AU  - Campiglio M
AD  - Molecular Targeting Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, 
      Italy.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - 0 (Antigens, CD)
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CDCP1 protein, human)
RN  - 0 (Cell Adhesion Molecules)
RN  - 0 (Neoplasm Proteins)
SB  - IM
MH  - Antigens, CD/analysis/genetics
MH  - Antigens, Neoplasm
MH  - Biomarkers, Tumor/analysis
MH  - Cell Adhesion Molecules/*analysis/genetics
MH  - Cell Line, Tumor
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Neoplasm Metastasis
MH  - Neoplasm Proteins/*analysis/genetics
MH  - Triple Negative Breast Neoplasms/*metabolism/*pathology
MH  - Tumor Microenvironment
PMC - PMC5342505
OTO - NOTNLM
OT  - CDCP1
OT  - CDCP1 copy number
OT  - metastasis
OT  - prognosis
OT  - triple-negative breast cancer
COIS- CONFLICTS OF INTEREST No potential conflicts of interest are disclosed by the 
      authors.
EDAT- 2016/09/15 06:00
MHDA- 2018/02/14 06:00
PMCR- 2016/10/25
CRDT- 2016/09/15 06:00
PHST- 2015/09/10 00:00 [received]
PHST- 2016/08/27 00:00 [accepted]
PHST- 2016/09/15 06:00 [pubmed]
PHST- 2018/02/14 06:00 [medline]
PHST- 2016/09/15 06:00 [entrez]
PHST- 2016/10/25 00:00 [pmc-release]
AID - 11935 [pii]
AID - 10.18632/oncotarget.11935 [doi]
PST - ppublish
SO  - Oncotarget. 2016 Oct 25;7(43):69649-69665. doi: 10.18632/oncotarget.11935.